89Bio starting Proof of Concept Trial for NASH therapy and announcing expansion of leadership team

89Bio, a clinical-stage biopharmaceutical company, today announced Thursday that the first patients have been screened in its proof of concept Phase 1b/2a clinical trial evaluating its investigational product candidate, BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), in NASH or patients with nonalcoholic fatty liver disease (NAFLD) and high risk of NASH.